First Experiences with 1% Pimecrolimus Cream Therapy in Prevention of AtopicEczema Flares in Children
Authors:
M. Salavec 1; H. Bučková 2
Authors‘ workplace:
Klinika nemocí kožních a pohlavních, Fakultní nemocnice Hradec Králové přednostka doc. MUDr. M. Nožičková, CSc. 2Dětské kožní oddělení, FN Brno - Dětská nemocnicepřednostka prim. MUDr. H. Bučková, Ph. D.
1
Published in:
Čes-slov Derm, , 2004, No. 1, p. 3-7
Category:
Overview
First experiences withnewtopicalimmunomodulating therapy of atopic dermatitis in 40 childrenhas been analyzed by authors. Parameters of long-term efficacy and safety were evaluated during 1year double-blind, randomised clinical study following the introduction of 1% pimecrolimus creaminto the topical treatment of atopic dermatitis. The novel therapeutic regimen was effective and moresafe than current conventional therapy, reducing the incidence of flares of atopic dermatitis inchildren. The therapy did not influence the skin recal antigen tests. Pimecrolimus-based regimenpatients required substantially less corticosteroids than those in control groups.
Key words:
pimecrolimus - atopic dermatitis - topical treatment
Labels
Dermatology & STDs Paediatric dermatology & STDsArticle was published in
Czech-Slovak Dermatology
2004 Issue 1
Most read in this issue
- First Experiences with 1% Pimecrolimus Cream Therapy in Prevention of AtopicEczema Flares in Children
- Scabies norvegica
- Androgenetic Alopecia
- Metastasizing Basal Cell Carcinoma